NCT06669234View on ClinicalTrials.gov

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

ALN-F1202

Administered per the protocol

DRUG

Matching Placebo

Administered per the protocol

Trial Locations (1)

3000

RECRUITING

Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven), Leuven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY